Allianz SE Buys Shares of 50,216 DexCom, Inc. (NASDAQ:DXCM)

Allianz SE purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 50,216 shares of the medical device company’s stock, valued at approximately $3,916,000.

A number of other hedge funds also recently modified their holdings of the business. Versant Capital Management Inc acquired a new position in DexCom in the 4th quarter worth $25,000. Private Trust Co. NA boosted its position in shares of DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after buying an additional 245 shares during the period. TD Private Client Wealth LLC grew its holdings in shares of DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after buying an additional 167 shares in the last quarter. Larson Financial Group LLC raised its position in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after buying an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC bought a new stake in DexCom in the 4th quarter valued at approximately $38,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity

In related news, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is owned by insiders.

DexCom Trading Down 2.5 %

DXCM stock opened at $67.74 on Friday. The stock has a market cap of $26.47 billion, a price-to-earnings ratio of 47.37, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a fifty day moving average price of $82.32 and a two-hundred day moving average price of $77.07. DexCom, Inc. has a one year low of $62.34 and a one year high of $141.99. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

DXCM has been the subject of several research reports. Cfra Research raised shares of DexCom to a “hold” rating in a research note on Friday, March 21st. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Canaccord Genuity Group raised their price objective on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Finally, Morgan Stanley upped their target price on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.